VNDA Share Price

Open 15.75 Change Price %
High 15.90 1 Day -0.05 -0.32
Low 15.57 1 Week -0.65 -3.96
Close 15.75 1 Month -0.80 -4.83
Volume 272841 1 Year 4.35 38.16
52 Week High 18.00
52 Week Low 11.41
VNDA Important Levels
Resistance 2 16.06
Resistance 1 15.93
Pivot 15.74
Support 1 15.57
Support 2 15.44
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
DCTH 0.11 -15.38%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.04 100.00%
LOCM 0.09 50.00%
CYTR 0.82 43.86%
TWER 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ZN 4.22 23.03%
ZN 4.22 23.03%
LMAT 33.94 19.51%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
DEST 1.71 -42.23%
TRGT 0.96 -41.46%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 3
As on 28th Jul 2017 VNDA Share Price closed @ 15.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 15.15 & Buy for SHORT-TERM with Stoploss of 15.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for July
1st Target up-side 17.99
2nd Target up-side 19.17
3rd Target up-side 20.36
1st Target down-side 14.61
2nd Target down-side 13.43
3rd Target down-side 12.24
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.